Early administration of ivabradine in patients with acute anterior ST-elevation myocardial infarction: a prospective, randomized, open-label study on in-hospital and short-term major adverse cardiac events and left ventricular function

Description

Omar Mohammed Al Hawwari and colleagues randomized three hundred patients with a major front-wall heart attack. They tested whether adding ivabradine protects the heart in the first months. Ivabradine is a pure heart-rate slowing drug. It was added to standard beta-blocker care. The open-label trial ran at Ain Shams University hospitals in patients whose resting rate stayed high.

By three months the ivabradine group's pumping fraction had improved more than the control group's, and their hearts' filling volume shrank while the controls' grew, signs of healthier remodeling after the attack. Final heart rate sat far lower in the treated group, in the low sixties against the mid-seventies. Assessors of the scans and events were blinded to allocation, strengthening the reading. The authors present early rate control beyond beta-blockade as a promising, gentle lever after this kind of infarction.

Catalog record

Source: https://europepmc.org/article/MED/PMC13597995